Sunifiram, also known by the laboratory code DM-235, is a synthetic cognitive research compound associated with the University of Florence pharmacology program and the broader racetam and ampakine research fields. It is often described as an ampakine-like compound because its reported effects are related to excitatory glutamatergic signaling, particularly AMPA-receptor function. The compound has attracted attention in nootropic communities because animal experiments reported effects on learning, memory, and pharmacologically induced amnesia. Those findings should not be confused with evidence of effectiveness in people: there are no robust randomized clinical trials establishing benefit, safety, pharmacokinetics, or an appropriate human dose.
Sunifiram is structurally different from piracetam rather than being a simple chemical form of it. Descriptions commonly emphasize a modified piperazine-containing scaffold and a much higher apparent potency in selected laboratory assays, with an often-repeated estimate of approximately 1,000 times the potency of piracetam. That estimate is not a validated clinical conversion factor and cannot be used to calculate a human dose. Commercial names and chemical descriptions can also be inconsistent; labels such as 1-BCP and piperazine-2-carboxamide should not be treated as reliable identity confirmation without analytical testing. Because the compound is not an approved medicine and has very limited human research, any nonclinical use carries substantial uncertainty.
Quick Reference
Member reference tables summarize the compound's research parameters.
Sunifiram has been evaluated in rodent learning and memory paradigms, including models involving experimentally induced cognitive impairment. These findings are preclinical and do not establish cognitive benefit in humans.
Amnesia-model research
Animal experiments have examined whether the compound modifies performance deficits associated with cholinergic disruption or other laboratory memory-impairment models.
Glutamatergic Signaling
Preliminary Data
AMPA-related hypotheses
Sunifiram is commonly described as an ampakine-like research compound. Its precise pharmacology remains incompletely characterized, and it should not be assumed to have the same effects as established AMPA-receptor modulators.
Intracellular signaling studies
Experimental work has implicated glutamatergic and cholinergic signaling pathways, but receptor selectivity, potency, and downstream effects in humans are not well defined.
Mood and Motivation Claims
Emerging Evidence
Subjective mood reports
Reports of altered motivation, mood, or sociability are anecdotal. Controlled clinical studies supporting these effects have not been established.
Potential overstimulation
Because subjective stimulation and anxiety-like effects are also reported, mood-related claims should not be interpreted as evidence of safety or therapeutic utility.
Human Evidence Gap
Emerging Evidence
No established therapeutic indication
Sunifiram is not an approved medicine for cognitive, mood, or neurological conditions. Robust human pharmacokinetic, dose-ranging, and efficacy data are lacking.
Unknown long-term risk profile
Published evidence does not adequately characterize chronic exposure, withdrawal effects, reproductive risks, or interactions with prescription medicines.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
The described verification process includes looking for a dated, batch-matched COA identifying sunifiram by an appropriate analytical method rather than a generic vendor statement.
Verified Marker
Independent HPLC or LC-MS identity testing
Prefer documentation from an identifiable third-party laboratory showing analyte identity and a stated purity result for the specific lot.
Verified Marker
Contaminant screening
A credible report includes relevant heavy-metal and microbiological testing, especially for oral powders or capsules intended for consumer sale.
Acceptable Range
Capsule mass and label accuracy
For capsules, verify the labeled milligram content, excipients, lot number, and expiration date; capsule-fill weight alone does not confirm active-compound content.
Quality Concern
Unverifiable purity or research-only disclaimer
Avoid products lacking batch-level analytical documentation, using only marketing claims, or presenting “research use only” material as a dietary supplement or medicine.
Effects of the potent ampakine CX614 on hippocampal and cortical synaptic transmission and plasticity Arai, A. C., Kessler, M., Rogers, G., et al., 2000, Journal of Pharmacology and Experimental Therapeutics